Stay updated with breaking news from Final Appraisal. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
INNOVATIVE ACCESS DEAL SECURED IN THE UK FOR LYNPARZA (OLAPARIB) TO TREAT BRCA-MUTATED CANCERS Olaparib is the first and only treatment available within NHS England for patients with germline BRCA mutations in early breast cancer (stage I-IIIA) and patients with metastatic castration-resistant prostate cancer (...
National Institute for Health and Care Excellence Backs Darzalex®▼ (daratumumab) in Combination with Velcade® (bortezomib), Thalidomide and Dexamethasone (DVTd) for Patients with Newly Diagnosed Multiple Myeloma High Wycombe, 22nd December 2021 – The Janssen Pharmaceutical Companies of Johnson &a...
Osimertinib will be made available via the Cancer Drugs Fund (CDF) to patients in England with completely resected early-stage IB-IIIA EGFR mutation-positive (EGFRm) non-small cell lung cancer (NSCLC).1
Investegate announcements from Great Portland Ests., Annual Financial Report